Skip to search formSkip to main contentSkip to account menu

VX 478

Known as: KVX 478, VX-478, Vertex VX478 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Amprenavir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
Synthesis of nucleoside analogs and new Tat protein inhibitors
Two studies, concerning the synthesis of original nucleoside analogs regarded as an application of heterochemistry on… 
2000
2000
Identifying and Characterizing HIV Protease Inhibitors.
HIV protease catalyzes the hydrolysis of specific peptide bonds of viral polyproteins, thus processing these polyproteins into… 
1998
1998
A computational study of the resistance of HIV-1 aspartic protease to the inhibitors ABT-538 and VX-478 and design of new analogues.
Recent experimental findings with HIV-1 protease (HIV-1 PR) mutants containing variations at four residues, M46I, L63P, V82T and… 
1998
1998
What's new, what's next?
  • D. Fakuda
  • Positive Directions news : a support and…
  • 1998
  • Corpus ID: 11721742
There are a number of new developments in the fight against the HIV epidemic. New drugs are being developed, results are being… 
1997
1997
Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem?
1996
1996
In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9.
Compound 141W94 (Vertex VX478) (3S)-tetrahydro-3-furyl N-[((S,2R)-3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl- 2… 
Review
1996
Review
1996
Rational approaches to resistance: using saquinavir.
AIM To review drug-resistance patterns of HIV protease inhibitors, with particular reference to saquinavir, and how resistance… 
Highly Cited
1995
Highly Cited
1995
Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy.
VX-478 is a potent inhibitor of human immunodeficiency virus type 1 (HIV-1) protease (Ki, 0.6 nM) and of HIV-1 replication in… 
1995
1995
Protease inhibitor update.
New clinical trial developments surrounding anti-HIV compounds, known as protease inhibitors, are discussed for the following… 
1995
1995
Viral resistance to protease inhibitors.
The development of HIV resistance to protease inhibitors, once thought not to be possible, is causing great concern among… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)